These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3816020)

  • 21. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K; Otton SV; Gram LF
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
    Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
    Woolhouse NM; Eichelbaum M; Oates NS; Idle JR; Smith RL
    Clin Pharmacol Ther; 1985 May; 37(5):512-21. PubMed ID: 3987174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
    Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
    Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.
    Dayer P; Leemann T; Striberni R
    Clin Pharmacol Ther; 1989 Jan; 45(1):34-40. PubMed ID: 2910636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
    Kaneko K; Atsumi T; Miyataka T
    Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
    Fromm MF; Hofmann U; Griese EU; Mikus G
    Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
    Brøsen K; Davidsen F; Gram LF
    Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
    Tyndale RF; Inaba T; Kalow W
    Drug Metab Dispos; 1989; 17(3):334-40. PubMed ID: 2568917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K; Gram LF
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
    Ho JW; Moody DE
    Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF
    Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sparteine oxidation is practically abolished in quinidine-treated patients.
    Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
    Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
    Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
    Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
    Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
    Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.